<DOC>
	<DOCNO>NCT02759588</DOCNO>
	<brief_summary>The purpose study determine GL-ONC1 oncolytic immunotherapy well tolerated anti-tumor activity patient diagnose recurrent ovarian cancer peritoneal carcinomatosis .</brief_summary>
	<brief_title>GL-ONC1 Oncolytic Immunotherapy Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>Ovarian cancer ( OC ) remain lethal gynecologic malignancy owe late detection , intrinsic acquire chemo-resistance remarkable heterogeneity . There unmet medical need develop new therapy modality . In preclinical study , GL-ONC1 , show ability preferentially locate , colonize destroy tumor cell 30 different human tumor , include ovarian cancer . GL-ONC1 investigate early stage clinical trial United States Europe via systemic delivery monotherapy combination therapy , via regional delivery monotherapy . GL-ONC1 treatment well tolerate across different malignancy , route administration , monotherapy well combination therapy protocol . The ability GL-ONC1 infect tumor tissue kill tumor cell demonstrate . In addition , virus-induced immune activation favorable anti-tumor immune response observe . Evidences anti-tumor efficacy clinical benefit also document .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Signed , write informed consent . Highgrade serous ( include Malignant Mixed Mullerian Tumor ( MMMT ) metastasis contain high grade epithelial carcinoma ) , endometrioid , clearcell ovarian cancer include : ( 1 ) platinumresistant ( recurrence progression &lt; 6 month ) ( 2 ) platinumrefractory ( progression platinumbased therapy ) ; patient must fail either least 2 consecutive therapy eligible additional cytotoxic therapy . Intermediate platinumsensitive patient ( recurrence disease 6 12 month last platinum compound treatment ) : Recurrent ovarian carcinoma least four prior individual treatment regimen include least two separate platinumbased therapy recurrence last platinumbased regimen le 12 month , unwilling unable undergo additional platinumbased cytotoxic therapy . Performance status ECOG 0 1 , life expectancy 6 month Has either measurable disease peritoneal cavity define RECIST 1.1 nonmeasurable disease peritoneal cavity confirm laparoscopy and/or elevate CA125 . Patients nonmeasurable disease identifiable PET/PETCT scan , elevate CA125 , and/or ascites , visible disease confirm laparoscopy also eligible . Able undergo IP injection . Adequate renal , hepatic bone marrow function . Tumors mucinous subtypes , nonepithelial ovarian cancer ( e.g. , Brenner tumor , Sexcord tumor ) . Unresolved bowel obstruction . Known central nervous system ( CNS ) metastasis . Known seropositivity HIV , hepatitis . History thromboembolic event within last 3 month . Pregnant breastfeed woman . Smallpox vaccination within 1 year study treatment . Clinically significant cardiac disease . Received prior gene therapy therapy cytolytic virus type . Receiving concurrent antiviral agent active vaccinia virus . Have know allergy ovalbumin egg product . Have clinically significant dermatological disorder ( e.g. , eczema , psoriasis , unhealed skin wound ulcer ) assess Investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>GL-ONC1</keyword>
	<keyword>oncolytic virus</keyword>
	<keyword>virotherapy</keyword>
	<keyword>Viral therapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>immune therapy</keyword>
	<keyword>vaccinia</keyword>
	<keyword>vaccinia virus</keyword>
	<keyword>Genelux</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>platinum resistant</keyword>
	<keyword>platinum refractory</keyword>
	<keyword>peritoneal carcinomatosis</keyword>
	<keyword>fallopian cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>abdominal cancer</keyword>
	<keyword>image</keyword>
	<keyword>carcinoma</keyword>
	<keyword>DNA virus</keyword>
	<keyword>neoplasm</keyword>
	<keyword>neoplasms histological type</keyword>
	<keyword>neoplasm , Glandular Epithelial</keyword>
	<keyword>Poxviridae infection</keyword>
	<keyword>Virus disease</keyword>
	<keyword>recurrent ovarian cancer</keyword>
	<keyword>intermediate platinum-sensitive</keyword>
</DOC>